Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Arcus Biosciences (NYSE:RCUS) reported positive late stage efficacy results for casdatifan, its investigational HIF-2a inhibitor, in late line renal cell carcinoma. The company released biomarker ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...

SAN FRANCISCO -- The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease ...

Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival (PFS) ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...